Kymriah™ (tisagenlecleucel) – New drug approval
August 30, 2017 – The FDA announced the approval of Novartis’ Kymriah (tisagenlecleucel), for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.
Download PDF
